|
SEC23IP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.21620002957457E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.61199999804529E-08 |
| Normal-vs-Stage2 |
1.044140E-04 |
| Normal-vs-Stage3 |
5.42949996074071E-09 |
| Normal-vs-Stage4 |
8.60440052541378E-10 |
| Stage1-vs-Stage2 |
9.451800E-01 |
| Stage1-vs-Stage3 |
1.598950E-01 |
| Stage1-vs-Stage4 |
1.965800E-02 |
| Stage2-vs-Stage3 |
3.211800E-01 |
| Stage2-vs-Stage4 |
6.355800E-02 |
| Stage3-vs-Stage4 |
2.358000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.95960000951112E-09 |
| Normal-vs-AfricanAmerican |
7.321900E-03 |
| Normal-vs-Asian |
1.45849999966252E-07 |
| Caucasian-vs-AfricanAmerican |
2.952400E-01 |
| Caucasian-vs-Asian |
5.370600E-01 |
| AfricanAmerican-vs-Asian |
1.733770E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.92669999346629E-10 |
| Normal-vs-Female |
2.57669999781385E-08 |
| Male-vs-Female |
7.242400E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.6405999960858E-08 |
| Normal-vs-Age(41-60Yrs) |
4.80270001546046E-09 |
| Normal-vs-Age(61-80Yrs) |
3.64579999967418E-07 |
| Normal-vs-Age(81-100Yrs) |
2.928500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.148800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.867200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.809200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.697400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.603800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.489800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.116790E-01 |
| Classical-VS-Follicular |
4.037800E-01 |
| Classical-VS-Other |
1.044630E-01 |
| Classical-VS-Normal |
6.45600000126478E-08 |
| Tall-VS-Follicular |
3.247600E-01 |
| Tall-VS-Other |
3.867000E-01 |
| Tall-VS-Normal |
7.64980000012017E-07 |
| Follicular-VS-Other |
2.493800E-01 |
| Follicular-VS-Normal |
2.09200000000909E-06 |
| Other-VS-Normal |
4.568100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.1210000028814E-08 |
| Normal-vs-N1 |
6.5127999993031E-08 |
| N0-vs-N1 |
2.149000E-01 |
|
|
